申请人:Astellas Pharma Inc.
公开号:EP2119716A1
公开(公告)日:2009-11-18
[PROBLEMS] Provided is a compound which has an antagonistic action on a muscarinic M3 receptor and is useful as an active ingredient of a prophylactic and/or therapeutic agent for an inflammatory disease such as a chronic obstructive pulmonary disease (COPD), asthma and the like.
[MEANS FOR SOLVING PROBLEMS] The present inventors have made studies on a compound having an antagonistic action on the binding of a muscarinic M3 receptor, and they have found that an aza-bridged-ring compound or a salt thereof has an antagonistic action on the binding of a muscarinic M3 receptor, thereby completing the present invention. The aza-bridged-ring compound of the present invention has an antagonistic action on the binding of a muscarinic M3 receptor, and can be used as a prophylactic and/or therapeutic agent for an inflammatory disease such as a chronic obstructive pulmonary disease (COPD), asthma and the like.
[问题]本发明提供了一种化合物,该化合物对毒蕈碱 M3 受体具有拮抗作用,可用作慢性阻塞性肺病 (COPD)、哮喘等炎症疾病的预防和/或治疗剂的活性成分。
[解决问题的方法]本发明者对一种对毒蕈碱类 M3 受体的结合具有拮抗作用的化合物进行了研究,他们发现一种杂环桥环化合物或其盐对毒蕈碱类 M3 受体的结合具有拮抗作用,从而完成了本发明。本发明的杂环桥环化合物对毒蕈碱类 M3 受体的结合具有拮抗作用,可用作慢性阻塞性肺病(COPD)、哮喘等炎症疾病的预防和/或治疗剂。